A pharmacogenetic analysis of the Canadian Cancer Trials Group MY.10 clinical trial of maintenance therapy for multiple myeloma.

Biology, University of New Brunswick, Saint John, NB, Canada; Southern Alberta Cancer Research Institute, University of Calgary, Calgary, AB, Canada; Hematology, Vancouver General Hospital, Vancouver, BC, Canada; Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax, NS, Canada; Oncology, Princess Margaret Hospital, Toronto, ON, Canada; Oncology, London Health Sciences Centre, London, ON, Canada; Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada; Centre for Individualized Medicine, Mayo Clinic Arizona, Scottsdale, AZ; Laboratory Medicine, Saint John Regional Hospital, Saint John, NB, Canada; Department of Internal Medicine, Queen’s University, Kingston, ON, Canada; Canadian Cancer Trials Group, Queen’s University, Kingston, ON, Canada; Juravinski Hospital and Cancer Centre and McMaster University, Hamilton ON, Canada; and Department of Oncology, Saint John Regional Hospital, Dalhousie University and University of New Brunswick, Saint John, NB, Canada